Upside, Downside Movers in the Morning

Avatar photo Doug Kass on October 20, 2026

Upside

– $RAPP +26% (Phase 2 RAP-219 trial met the primary and secondary endpoints in bipolar mania)

– $MSCI +5.9% (Q3 earnings and revenue topped expectations)

– $EFX +5.5% (sharply positive initial reaction to Q3 results released before the bell)

– $HTZ +5.0% (Oro Mobility secured an $80 million strategic equity investment to accelerate its standalone growth)

– $HAL +4.4% (Q3 earnings and revenue beat expectations)

– $SNY +2.4% (no clear fresh catalyst identified; unusually strong, liquid ADR move)

– $APA +1.9%, $XOM +1.2%, $CVX +1.4%, $COP +1.5%, $OXY +1.6%, $SLB +1.4% (energy names rise as crude jumps on renewed Middle East supply risks)

– $VICR +1.7% (Q3 product and royalty revenue surged and gross margin expanded sharply)

Downside

– $GM -7.6% (Q3 beat, but the full-year profit range was narrowed with the upper end cut, disappointing expectations for another guidance raise)

– $GPC -6.3% (quarter narrowly beat, but the full-year earnings range was narrowed and its upper end cut)

– $STLD -5.4% (Q3 profit missed consensus and fell below the company’s own guidance despite a revenue beat)

– $AAOI -4.6%, SKHY -4.8%, COHR -3.5%, SNDK -3.2%, MU -2.7%, LITE -2.7% (AI hardware, memory and optical names fall as renewed bubble concerns and a weak Korean AI listing pressure the trade)

– $CCK -4.3% (Q3 reaction turns negative as rising input costs offset strong beverage-can volume growth)

– $CRWV -3.9%, NBIS -4.4%, IREN -4.3% (debt-heavy AI-infrastructure names fall as borrowing-cost and funding concerns deepen)

– $GE -3.6% (Q3 beat and the outlook was raised, but shares slip in a high-expectations sell-the-news reaction)

– $BHP -3.0% (quarterly copper production fell 19% on lower grades, maintenance and operational disruptions)

– $AAPL -1.4% (Loop Capital downgrades to Hold from Buy and cuts its target on weaker iPhone shipment expectations)

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on October 1, 2026

Upside

– $MEDS +36% (preliminary September pharmacy revenue exceeded $1M, rising more than 66% from July)

– $ACN +17% (Q4 beat with $22.2B of bookings and stronger operating margins)

– $ABAT +13% (receives federal approval to export up to $100M of recycled black-mass material)

– $QSI +13% (no clear fresh catalyst identified; unusually large move on heavy premarket volume)

– $VICR +12% (raises Q3 sequential revenue-growth outlook to more than 30% from more than 20% on higher royalties)

– $GLOB +11%, $CTSH +7.5%, $INFY +8.1%, $EPAM +6.6% (IT-services names rise in read-through from ACN’s Q4 beat, strong bookings and margin performance)

– $INSG +9.6% (completes fixed-wireless-access acquisition expected to roughly double revenue and expand its global footprint)

– $IBM +5.7% (unveils a self-hosted enterprise AI model)

– $NU +5.6% (rebounds after clarifying it is not pursuing the reported UK digital-bank acquisition)

– $GLUE +4.8% (Phase 1 GFORCE-1 results showed normalization of key pathogenic drivers of cardiovascular disease)

– $RKLB +4.3% (signs its largest commercial launch agreement, covering 20 missions and lifting total backlog above 100 launches)

– $MKC +3.7% (Q3 profit and sales beat expectations as pricing offset softer volumes)

– $SNPS +3.7% (signs a multiyear silicon-IP and engineering-software agreement valued above $1B)

– $CEG +3.4% (signs a 20-year, 690-megawatt nuclear power agreement supporting more than $3B of infrastructure investment)

– $TARA +3.3% (updated 12-month Phase 2 ADVANCED-2 data showed durable responses in BCG-naïve bladder-cancer patients)

Downside

– $FHTX -43% (Phase 1 review leads to discontinuation of FHD-909 expansion and a related degrader program; workforce cut about 40%)

– $ANGO -16% (no clear fresh catalyst identified; unusually large, high-volume premarket decline)

– $LQDA -12% (federal court rules YUTREPIA infringed two pulmonary-hypertension patent claims)

– $ZELA -12% (Phase 3 obesity trial met its endpoints, but weight-loss efficacy fell short of investor expectations)

– $BGIN -10% (slides following first-half results)

– $IVA -10% (extends weakness following unaudited first-half results and corporate update)

– $FLOC -8.5% (no clear fresh catalyst identified; unusually large, liquid premarket decline)

– $ENTX -6.4% (no clear fresh catalyst identified after healthcare and company-news checks)

Upside, Downside Movers

Avatar photo Doug Kass on September 22, 2026

Upside

– $GRML +44% (extends the high-volume Greenland critical-minerals momentum rally)

– $VKTX +25% (positive VK2735 maintenance data showed strong weight loss and high retention with biweekly and monthly dosing)

– $VICR +8.7% (raises Q3 sequential revenue-growth guidance to more than 20% from nearly 10% on V4PD-license royalties)

– $ONON +8.0% (sets high-teens constant-currency sales growth and 22%+ EBITDA-margin targets through 2029 and authorizes a $1B buyback)

– $SHOP +5.1% (no clear fresh catalyst identified; unusually large premarket move in a highly followed stock)

– $RCL +2.4%, CCL +3.0%, NCLH +2.7% (cruise operators rise as crude drops, easing fuel-cost pressure)

– $FSLR +1.8% (rate-sensitive solar shares benefit as Treasury yields retreat)

Downside

– $CLDX -20% (positive Phase 3 CSU results trigger a sell-the-news reaction after the anticipated binary readout)

– $DAVA -13% (CFO placed on leave amid an internal accounting investigation disclosed in a 6-K)

– $LH -6.2%, DGX -6.9% (CMS proposes laboratory reimbursement cuts of up to 15% beginning in 2027)

– $VLO -2.1%, $PSX -2.0% (energy names fall as crude drops on easing geopolitical risk)

– $STX -1.4%, WDC -1.4% (storage names pull back with the semiconductor complex after the prior session’s AI-driven rally)

SOURCE: Trade The News

Upside, Downside Movers in the Morning

Avatar photo Doug Kass on September 17, 2026

Upside

– $AEMD +403% (merger agreement with North Immunology adds an IL-13 x IL-18 bispecific-antibody program for atopic dermatitis)

– $GNRC +30% (Amazon supply agreement includes $2.4B of backup-generator deliveries expected during 2027-2028)

– $VEEA +30% (non-binding combination term sheet with NovaGen targets a $750M AI-health platform)

– $DTSS +12% (strategic cooperation expands into AI-powered elderly-care robots in China)

– $MEDS +12% (Helomics acquisition expands its cancer-diagnostics and precision-oncology platform)

– $VICR +12% (licenses its vertical power-delivery technology to a leading AI OEM)

– $NBIS +9.0% (reported AI-compute price increases signal stronger pricing power amid constrained capacity)

– $IREN +5.5%, CIFR +6.3% (AI-compute peers gain on the pricing-power read-through from NBIS)

– $APLD +5.8%, HUT +5.0%, WULF +4.7% (Wells Fargo initiates the data-center infrastructure names at Overweight)

– $NOK +5.0% (expands its Microsoft partnership by integrating network-automation data tools with Microsoft Fabric)

– $BE +4.5%, $GEV +3.3% (data-center power names gain as the Amazon-GNRC agreement reinforces hyperscaler power demand)

– LCID +4.2% (partners with Bolt to deploy at least 25,000 Level 4 autonomous vehicles across Europe)

– QGEN +3.5% (traders circulating German press report saying Qiagen attracts interest from KKR, Advent, TPG)

– GLW +3.7%, ANET ($ANET) +2.7%, CIEN +3.2% (AI networking and optical names rise as compute pricing points to continued infrastructure tightness)

– MRVL ($MRVL) +3.5%, LRCX +3.6%, INTC +3.2%, TER +3.6%, AMAT +3.2%, KLAC +3.2% (semiconductors rebound with technology shares after the Fed decision clears a major policy-event overhang)

Downside

– LGVN -49% (Phase 2b ELPIS II trial in hypoplastic left heart syndrome missed its primary efficacy endpoint)

– DLXY -45% (reverses sharply after a non-binding LOI covering up to a 48% interest in a Kazakhstan oil-field project)

– FLNC -22% (cuts FY guidance as supply-chain issues and delays ramping its Houston manufacturing facility drive a much larger expected loss)

– S -3.9% (no clear fresh catalyst identified; notable liquid cybersecurity move)

– BDX -3.5% (no clear fresh catalyst identified; unusually large premarket move in the medical-device name)

– LEN ($LEN) -1.3% (quarter missed and forward guidance disappointed as affordability pressure continued to weigh on homebuilding demand)

Source: Trade The News